


About Spherix Global Insights

Spherix is the world’s leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Seven Areas



Dermatology



Nephrology



Gastroenterology



CNS



Rheumatology



Ophthalmology



Hematology



Oncology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications	
MARKET DYNAMIX	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.
LAUNCH DYNAMIX	Published monthly, Launch Dynamix tracks a new brand’s first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmaskes real patient management patterns and uncovers the “why” behind treatment decisions.
PATIENT VOICE DYNAMIX	An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.

For a complete index of available reports, visit [www.clientportal.spherixglobalinsights.com](http://www.clientportal.spherixglobalinsights.com)



## Alopecia Areata

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Alopecia Areata, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Leqselvi (SUN Pharma) in Alopecia Areata, US</li></ul>

## Atopic Dermatitis

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Atopic Dermatitis, US</li><li>Atopic Dermatitis, JP</li></ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Atopic Dermatitis, EU5</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Ebglyss (Eli Lilly) in Atopic Dermatitis, US</li><li>Nemluvio (Galderma) in Atopic Dermatitis, US</li><li>Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Atopic Dermatitis, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Atopic Dermatitis, US</li></ul>

## Chronic Spontaneous Urticaria

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Chronic Spontaneous Urticaria, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Dupixent (Sanofi/Regeneron) in CSU, US</li><li>Rhapsido (Novartis) in CSU, US</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Chronic Spontaneous Urticaria, US</li></ul>

## Cross Indications / Specialty

SPECIAL TOPIX	<ul style="list-style-type: none"><li>Biologic Coordinators Across Dermatology, US</li><li>Payer Management Strategies, US</li></ul>
---------------	--

## Hidradenitis Suppurativa

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Hidradenitis Suppurativa, US</li><li>Hidradenitis Suppurativa, EU5</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Bimzelx (UCB) in Hidradenitis Suppurativa, US</li></ul>

## Plaque Psoriasis

REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Plaque Psoriasis, US</li><li>Plaque Psoriasis, EU5</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Icotrokinra (J&amp;J) in Plaque Psoriasis, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Plaque Psoriasis, US</li></ul>
SPECIAL TOPIX	<ul style="list-style-type: none"><li>The Oral Opportunity in Plaque Psoriasis, US</li></ul>

## Prurigo Nodularis

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Prurigo Nodularis, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Nemluvio (Galderma) in Prurigo Nodularis, US</li></ul>

## Other Dermatology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Asthma, US</li><li>Asthma, EU</li><li>Chronic Obstructive Pulmonary Disease, US</li><li>Chronic Obstructive Pulmonary Disease, EU</li><li>Vitiligo, US</li></ul>
----------------	--

### Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



## Eosinophilic Esophagitis

MARKET  
DYNAMIX

- Eosinophilic Esophagitis, US

## Inflammatory Bowel Disease

MARKET  
DYNAMIX

- Crohn's Disease, JP
- Ulcerative Colitis, JP

REALTIME  
DYNAMIX

- Crohn's Disease, US
- Crohn's Disease, EU5
- Ulcerative Colitis, US
- Ulcerative Colitis, EU5

LAUNCH  
DYNAMIX

- Tremfya (Janssen) in Crohn's Disease, US
- Omvoh (Eli Lilly) in Crohn's Disease, US
- Tremfya (Janssen) in Ulcerative Colitis, US

PATIENT CHART  
DYNAMIX

- Inflammatory Bowel Disease New Starts, US
- Inflammatory Bowel Disease Switching, US
- Inflammatory Bowel Disease Switching, EU5

PATIENT VOICE  
DYNAMIX

- Inflammatory Bowel Disease, US

SPECIAL  
TOPIX

- Biologic Coordinators in Gastroenterology, US
- The Role of APPs in IBD

## Obesity

MARKET  
DYNAMIX

- Obesity, US

LAUNCH  
DYNAMIX

- Oral Semaglutide (Novo Nordisk) in Obesity, US
- Orforglipron (Eli Lilly) in Obesity, US
- CagriSema (Novo Nordisk) in Obesity, US

## MASH

MARKET  
DYNAMIX

- MASH, US
- MASH, EU5

LAUNCH  
DYNAMIX

- Rezdiffra (Madrigal) in MASH, US
- Wegovy (Novo Nordisk) in MASH, US

PATIENT CHART  
DYNAMIX

- MASH, US

SPECIAL  
TOPIX

- MASH Screening and Management among PCPs and Endocrinologists, US

## Other Gastroenterology Indications

MARKET  
DYNAMIX

- Celiac Disease, US
- Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US (2025)

REALTIME  
DYNAMIX

- Irritable Bowel Syndrome, US

LAUNCH  
DYNAMIX

- Iqirvo (Ipsen) in Primary Biliary Cholangitis, US
- Linerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, US
- Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US

SPECIAL  
TOPIX

- The Business of Gastroenterology, US

## Cross Specialty

SPECIAL  
TOPIX

- Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



# 2026 Rheumatology Publications



Lupus	
MARKET DYNAMIX	<ul style="list-style-type: none"><li>Cutaneous Lupus, US (2026 refresh)</li><li>Systemic Lupus Erythematosus, US</li><li>Systemic Lupus Erythematosus Pipeline Refresh, US</li><li>Systemic Lupus Erythematosus, EU5</li><li>Lupus Nephritis, China</li></ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Lupus Nephritis, US</li><li>Lupus Nephritis, EU5</li><li>Lupus Nephritis, Brazil</li><li>Lupus Nephritis, Canada</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Gazyva (Genentech) in Lupus Nephritis, US</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Lupus Nephritis, US</li><li>Systemic Lupus Erythematosus , US</li><li>Systemic Lupus Erythematosus &amp; Lupus Nephritis, EU5</li><li>Cutaneous Lupus, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Systemic Lupus Erythematosus &amp; Lupus Nephritis, US</li></ul>

Spondyloarthritis (AS, nr-AxSpA, and PsA)	
MARKET DYNAMIX	<ul style="list-style-type: none"><li>Ankylosing Spondylitis &amp; nr-AxSpA, US</li><li>Ankylosing Spondylitis &amp; nr-AxSpA, EU5 (2025)</li><li>Psoriatic Arthritis, EU5 (2025)</li></ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Psoriatic Arthritis, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Bimzelx (UCB) in AS &amp; nr-AxSpA, US</li><li>Bimzelx (UCB) in Psoriatic Arthritis, US</li><li>Sotyktu (BMS) in Psoriatic Arthritis, US*</li></ul>

Other Rheumatology Indications	
MARKET DYNAMIX	<ul style="list-style-type: none"><li>Idiopathic Inflammatory Myopathies, US (2026 Refresh)</li><li>Rheumatoid Arthritis, US (2026 Refresh)</li><li>Rheumatoid Arthritis, EU5 (2025)</li><li>Sjogren's Disease, US (2025)</li><li>Systemic Sclerosis, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Rinvoq (AbbVie) in Giant Cell Arteritis, US</li><li>Ianalumab (Novartis) in Sjogren's Disease, US*</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Systemic Sclerosis, US</li></ul>
SPECIAL TOPIX	<ul style="list-style-type: none"><li>ILD in Rheumatology, US (2026 Refresh)</li><li>Cell Therapy in Rheumatology, US</li><li>Biologic Coordinators Across Rheumatology, US</li></ul>
Cross Specialty	
SPECIAL TOPIX	<ul style="list-style-type: none"><li>Payer Management Strategies, US</li></ul>

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas

\*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



## Rare Disease

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Focal Segmental Glomerulosclerosis, US</li><li>Membranous Nephropathy, US</li></ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>IgA Nephropathy, US</li><li>IgA Nephropathy, EU5</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Fabhalta in C3G</li><li>Empaveli in C3G</li><li>Fabhalta in IgAN</li><li>Vanrafia in IgAN</li><li>Sibeprenlimab in IgAN</li><li>Filspari in FSGS*</li><li>Atacicept in IgAN*</li><li>Povetacicept in IgAN*</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Focal Segmental Glomerulosclerosis, US</li><li>IgA Nephropathy, US</li><li>IgA Nephropathy, EU5</li><li>IgA Nephropathy, JP</li><li>IgA Nephropathy, China</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>IgA Nephropathy, US</li></ul>

## Lupus Nephritis

REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Lupus Nephritis, US (2025)</li><li>Lupus Nephritis, EU5 (2025)</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Lupus Nephritis, US (2025)</li></ul>

## CKD, Dialysis & Transplant

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Transplant/AMR, US</li></ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Dialysis–Nephrologists, US</li><li>Dialysis, Renal Dietitians/NP/PA, US</li><li>Hyperkalemia, US (2025)</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Vafseo (Akebia) in Renal Anemia, US</li><li>OLC (Unicycive) in Hyperphosphatemia, US*</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Chronic Kidney Disease, Non-Dialysis, Nephrologists, US</li><li>Chronic Kidney Disease, Non-Dialysis, PCPs, US</li><li>Dialysis, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Chronic Kidney Disease, US</li></ul>
SPECIAL TOPIX	<ul style="list-style-type: none"><li>Feedback from ASN Kidney Week, US</li></ul>

## Cross Specialty

SPECIAL TOPIX	<ul style="list-style-type: none"><li>Payer Management Strategies, US</li></ul>
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas

\*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



Alzheimer’s Disease

MARKET DYNAMIX	• Alzheimer’s Disease, US
PATIENT VOICE DYNAMIX	• Alzheimer’s Disease, US

Migraine

REALTIME DYNAMIX	• Migraine, 2 Wave, US
------------------	------------------------

Multiple Sclerosis

MARKET DYNAMIX	• Multiple Sclerosis, US
LAUNCH DYNAMIX	• Tolebrutinib, (Sanofi) nrSPMS, US

Psychiatric Indications

MARKET DYNAMIX	• Psychosis in Schizophrenia, US • Major Depressive Disorder (MDD), US • Schizophrenia, US
----------------	--

Generalized Myasthenia Gravis

REALTIME DYNAMIX	• Generalized Myasthenia Gravis, US • Generalized Myasthenia Gravis, EU5
PATIENT CHART DYNAMIX	• Generalized Myasthenia Gravis, US • Generalized Myasthenia Gravis, EU5
PATIENT VOICE DYNAMIX	• Generalized Myasthenia Gravis, US
LAUNCH DYNAMIX	• Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US • Imaavy, (J&J) Generalized Myasthenia Gravis (gMG), US • Gefurulumab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US* • Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*

Other Neurology Indications

MARKET DYNAMIX	• Chronic Inflammatory Demyelinating Polyneuropathy, US • Epilepsy, US (2025)
SPECIAL TOPIX	• Cell Therapy in Neurology Indications, US

Cross Specialty

SPECIAL TOPIX	• Payer Management Strategies, US
---------------	-----------------------------------

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas





## Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Diabetic Macular Edema &amp; AMD, US</li></ul>
------------------	--

## Cross Specialty

SPECIAL TOPIX	<ul style="list-style-type: none"><li>Payer Management Strategies, US</li></ul>
---------------	---

## Neovascular Age-Related Macular Degeneration

PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Age-Related Macular Degeneration, US</li></ul>
-----------------------	--

## Other Ophthalmology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Diabetic Retinopathy, US</li><li>Geographic Atrophy, US (2025)</li><li>Glaucoma, US (2025)</li><li>Thyroid Eye Disease (TED), US (2025)</li></ul>
SPECIAL TOPIX	<ul style="list-style-type: none"><li>Gene Therapies in Retina, US</li></ul>

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas



## Bleeding Disorders

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Hemophilia A &amp; B, US</li><li>Hemophilia A &amp; B, EU5</li><li>Von Willebrand Disease, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Qfitlia in Hemophilia A &amp; B</li><li>Hympavzi in Hemophilia A &amp; B</li><li>Alhemo in Hemophilia A &amp; B</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>People with Bleeding Disorders</li></ul>
SPECIAL TOPIX	<ul style="list-style-type: none"><li>Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders</li></ul>

## Hemoglobinopathies

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Sickle Cell Disease, US</li><li>Thalassemia, US</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Mitapivat in Thalassemia*</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Sickle Cell Disease, US</li><li>Thalassemia, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Sickle Cell Disease, US</li></ul>

## Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Paroxysmal Nocturnal Hemoglobinuria, US</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Paroxysmal Nocturnal Hemoglobinuria, US</li></ul>

## Other Benign Hematology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"><li>Autoimmune Hemolytic Anemia (US) (2025)</li><li>Warm Autoimmune Hemolytic Anemia (w-AIHA)</li><li>Immune Thrombocytopenic Purpura (ITP)</li></ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Nipocalimab in w-AIHA*</li><li>Wayrilz in ITP</li></ul>

## Cross Specialty

SPECIAL TOPIX	<ul style="list-style-type: none"><li>Payer Management Strategies, US</li></ul>
---------------	---

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas





Acute Myeloid Leukemia	
LAUNCH DYNAMIX	<ul style="list-style-type: none"><li>Acute Myeloid Leukemia, US</li></ul>
MARKET DYNAMIX	<ul style="list-style-type: none"><li>Market Dynamix, US</li></ul>

B-Cell Malignancies	
MARKET DYNAMIX	<ul style="list-style-type: none"><li>B-Cell Malignancies, US</li><li>Large B-Cell Lymphoma, EU</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Large B-Cell Lymphoma, US</li><li>Chronic Lymphocytic Leukemia, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>B-Cell Malignancies, US</li></ul>

Multiple Myeloma	
MARKET DYNAMIX	<ul style="list-style-type: none"><li>Multiple Myeloma, EU5</li></ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>Multiple Myeloma, US</li></ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"><li>Multiple Myeloma, US</li></ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"><li>Multiple Myeloma, US</li></ul>
SPECIAL TOPIX	<ul style="list-style-type: none"><li>Smoldering Myeloma, US</li></ul>

Myeloproliferative Neoplasms (MPN)	
MARKET DYNAMIX	<ul style="list-style-type: none"><li>Myeloproliferative Neoplasms, US</li></ul>
Solid Tumors	
REALTIME DYNAMIX	<ul style="list-style-type: none"><li>PD-1 Inhibition in Solid Tumors, US</li></ul>
Cross Specialty	
SPECIAL TOPIX	<ul style="list-style-type: none"><li>Payer Management Strategies, US</li></ul>

Key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
	SPECIAL TOPIX	Current events on specific interest areas



**Looking for more?  
Visit the Spherix Portal**

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

**Create your free account at  
[www.clientportal.spherixglobalinsights.com](https://www.clientportal.spherixglobalinsights.com)**